Gynecomastia: what causes male breast tissue, and what the evidence supports

Gynecomastia — genuine enlargement of the male breast from proliferation of glandular tissue — is common and, in the great majority of cases, benign [s2]. In a population-based study of 19,640 males aged 10 to 25, roughly three-quarters of cases (74.3%) were idiopathic, 23.1% were medication-related, and only 3.4% were linked to an underlying disease [s1]. The condition is best understood not as one thing but as a physical sign that is usually a normal developmental variant and occasionally a clue to something else.

What it is, and what it is not

Gynecomastia is the growth of true glandular breast tissue in males, driven by a relative imbalance between oestrogen and androgen activity [s2]. That distinguishes it from what is sometimes loosely called "man boobs" — the accumulation of fatty tissue in the chest without glandular growth, which is a feature of excess weight rather than the gland itself. The two can coexist, which is one reason obesity features so heavily in who is diagnosed.

In adolescence, the dominant cause is physiological, or pubertal, gynecomastia, attributed to the temporary hormonal shifts of puberty [s2]. Its natural history is reassuring: it is typically transient and resolves on its own within several months, though in some boys it can take a few years [s2]. Understanding that trajectory is much of the management, because the default expectation is resolution rather than progression [s2].

What the large dataset shows

The 19,640-male analysis is useful precisely because it is large enough to put numbers on the causes across childhood and young adulthood [s1]. Idiopathic cases — no identifiable cause — were the clear majority at 74.3%, followed by medication-related cases at 23.1% and pathology-associated cases at 3.4% [s1]. The pattern shifted with age: obesity-related and familial cases predominated in younger children, while the share attributable to underlying pathology rose with age [s1].

Body weight was a strong thread. Morbid obesity was associated with a markedly higher rate of surgery — 5.2% versus 2.1% in non-obese patients [s1]. When the researchers modelled which factors independently predicted eventually having surgery, the associations were telling: older age (odds ratio 1.20) and higher body-mass-index z-score (odds ratio 1.30) each raised the odds modestly, having two or more affected siblings raised them sharply (odds ratio 8.35), and a testicular tumour raised them most of all (odds ratio 14.06) [s1]. The model discriminated well, with an area under the curve of 0.973 [s1].

The signals that warrant a closer look

Those last two figures are the clinically important ones, and they are why gynecomastia is not simply dismissed. The very high odds ratio for testicular tumour reflects that, rarely, breast tissue growth is the visible sign of a hormone-producing tumour — which is why a testicular examination is part of a proper work-up [s1]. The strong familial signal points toward inherited or syndromic causes in a subset of cases [s1]. And because roughly a quarter of cases in this young population were medication-related, a review of drug exposures is standard [s1].

The paediatric-endocrinology literature frames the task the same way: the point of evaluation is to separate the common, self-limited developmental variant from the minority of cases that signal an endocrine disease, using history, examination and targeted laboratory testing [s2]. That is a diagnostic sorting exercise, not a reason for alarm in most boys.

What the evidence supports doing

For the typical pubertal case, the evidence supports watchful waiting, because most resolve without treatment [s2]. Where gynecomastia is persistent and causing psychosocial distress, surgical correction is an option, and the dataset above shows it is used more often in older adolescents, in those with higher BMI, and in the pathology-associated cases [s1]. Any decision about medication or surgery is a clinical one that depends on the cause, duration and impact, and is outside what this article can advise.

The overall message mirrors a lot of honest men's-health writing: a common, visible change that provokes real anxiety is, most of the time, benign and self-limited — while a small, identifiable minority of cases genuinely matters, which is exactly why evaluation is worthwhile [s1] [s2]. Because a hormone-producing testicular tumour is one of those uncommon causes, our explainer on testicular cancer is a useful companion, as is our review of what testosterone therapy trials actually show and of the testosterone-optimisation trend.

This article is informational and is not medical advice. New or persistent breast tissue changes should be evaluated by a clinician.